Parabilis Medicines Revenue
Biotechnology Research • 
Cambridge, Massachusetts, United States • 101-200 Employees
Parabilis Medicines revenue & valuation
| Annual revenue | $5,000,000 |
| Revenue per employee | $30,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $16,000,000 |
| Total funding | No funding |
Key Contacts at Parabilis Medicines
Mousa Jafari
Director, Drug Product Development
Kailene Simon
Senior Director, Head Of Biochemistry And Biophysics
Varun Shivashankar
Associate Director, Machine Learning
Santosh Kumar Choudary
Associate Director
John Santa Maria
Associate Director Of Cheminformatics
Xinwei Han
Associate Director, Computational Biology
Amber Wells
Senior Director, Clinical Science
Mackenzie Shannon
Associate Director, New Product Planning
Wade Berry
Associate Director Clinical Operations
Kerry Marasa Cadigan
Associate Director, People Ops
Company overview
| Headquarters | 30 Acorn Park Dr, Cambridge, MA 02140, US |
| Phone number | +16179459510 |
| Website | |
| NAICS | 541714 |
| Founded | 2016 |
| Employees | 101-200 |
| Socials |
Parabilis Medicines Email Formats
Parabilis Medicines uses 4 email formats. The most common is {first name}{last name} (e.g., johndoe@fogpharma.com), used 78.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@fogpharma.com | 85.3% |
{first initial}{last name} | jdoe@fogpharma.com | 10.7% |
{last name}{last name} | doedoe@fogpharma.com | 2.5% |
About Parabilis Medicines
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors. For more information, please visit: www.parabilismed.com
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Parabilis Medicines has 71 employees across 15 departments.
Departments
Number of employees
Funding Data
Parabilis Medicines has never raised funding before.
Parabilis Medicines Tech Stack
Discover the technologies and tools that power Parabilis Medicines's digital infrastructure, from frameworks to analytics platforms.
CDN
WordPress plugins
Font scripts
JavaScript libraries
Tag managers
Miscellaneous
Programming languages
Miscellaneous
Font scripts
Blogs
JavaScript libraries
Analytics
Belgium
Spain
Frequently asked questions
4.8
40,000 users
